Xenon Pharmaceuticals Inc.
XENE
$55.00
-$0.78-1.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 7.50M | 7.50M | 7.50M | 7.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 7.50M | 7.50M | 7.50M | 7.50M |
| Cost of Revenue | 328.25M | 300.94M | 272.71M | 252.63M | 227.34M |
| Gross Profit | -328.25M | -293.44M | -265.21M | -245.13M | -219.84M |
| SG&A Expenses | 84.41M | 79.63M | 75.57M | 72.99M | 73.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 412.66M | 380.57M | 348.28M | 325.62M | 300.50M |
| Operating Income | -412.66M | -373.07M | -340.78M | -318.12M | -293.00M |
| Income Before Tax | -385.15M | -344.89M | -309.70M | -282.60M | -255.52M |
| Income Tax Expenses | -1.98M | 1.02M | -3.37M | -4.37M | -4.07M |
| Earnings from Continuing Operations | -383.17 | -345.91 | -306.33 | -278.23 | -251.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -383.17M | -345.91M | -306.33M | -278.23M | -251.45M |
| EBIT | -412.66M | -373.07M | -340.78M | -318.12M | -293.00M |
| EBITDA | -410.19M | -370.53M | -338.18M | -315.50M | -290.36M |
| EPS Basic | -4.70 | -4.36 | -3.88 | -3.54 | -3.22 |
| Normalized Basic EPS | -2.95 | -2.72 | -2.45 | -2.25 | -2.04 |
| EPS Diluted | -4.70 | -4.36 | -3.88 | -3.54 | -3.22 |
| Normalized Diluted EPS | -2.95 | -2.72 | -2.45 | -2.25 | -2.04 |
| Average Basic Shares Outstanding | 325.67M | 317.02M | 315.28M | 313.95M | 312.67M |
| Average Diluted Shares Outstanding | 325.67M | 317.02M | 315.28M | 313.95M | 312.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |